PMID- 27471625
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160729
LR  - 20231105
IS  - 2162-4011 (Print)
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Linking)
VI  - 5
IP  - 6
DP  - 2016 Jun
TI  - Investigating the association between allergen-specific immunoglobulin E, cancer 
      risk and survival.
PG  - e1154250
LID - 10.1080/2162402X.2016.1154250 [doi]
LID - e1154250
AB  - Prior findings linking allergy and cancer have been inconsistent, which may be 
      driven by diverse assessment methods. We used serum specific immunoglobulin E 
      (IgE) against common inhalant allergens that was assessed prior to cancer 
      diagnosis in studying this association. We selected 8,727 Swedish men and women 
      who had measurements of serum allergen-specific IgE and total IgE between 1992 
      and 1996. Multivariable Cox regression using age as a timescale was performed to 
      assess the associations of IgE sensitization, defined by any levels of serum 
      specific IgE >/=35 kU/L, with risk of overall and specific cancers. A test for 
      trend was performed by assigning scores derived from allergen-specific IgE levels 
      at baseline as an ordinal scale. Kaplan-Meier curves and log-rank test were used 
      to assess cancer survival by IgE sensitization status. During a mean follow-up of 
      16 year, 689 persons were diagnosed with cancer. We found an inverse association 
      between IgE sensitization and cancer risk, with a hazard ratio (HR) of 0.83 and 
      95% confidence intervals (CI) of 0.70-0.99. A similar trend was seen with 
      specific IgE scores overall (Ptrend = 0.007) and in women (Ptrend = 0.01). 
      Although IgE sensitization was not associated with risk of common site-specific 
      cancers, serum specific IgE scores were inversely associated with melanoma risk 
      in men and women combined, and with risk of female breast and gynecological 
      cancers combined. No association with survival was observed. The association 
      between circulating IgE levels and incident cancer may point toward a role of 
      T-helper 2 (TH2)-biased response in development of some cancers.
FAU - Wulaningsih, Wahyu
AU  - Wulaningsih W
AD  - Cancer Epidemiology Group, Division of Cancer Studies, King's College London, 
      London, UK; Division of Hematology/Oncology, Faculty of Medicine, Gadjah Mada 
      University, Yogyakarta, Indonesia.
FAU - Holmberg, Lars
AU  - Holmberg L
AD  - Cancer Epidemiology Group, Division of Cancer Studies, King's College London, 
      London, UK; Department of Surgical Sciences, Uppsala University Hospital, 
      Uppsala, Sweden; Regional Cancer Centre, Uppsala, Sweden.
FAU - Garmo, Hans
AU  - Garmo H
AD  - Cancer Epidemiology Group, Division of Cancer Studies, King's College London, 
      London, UK; St. John's Institute of Dermatology, Division of Genetics and 
      Molecular Medicine, Faculty of Life Sciences and Medicine, King's College London, 
      NIHR Biomedical Research Centre at Guy's and St. Thomas's Hospitals and King's 
      College London, London, UK.
FAU - Karagiannis, Sophia N
AU  - Karagiannis SN
AD  - St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, 
      Faculty of Life Sciences and Medicine, King's College London, NIHR Biomedical 
      Research Centre at Guy's and St. Thomas's Hospitals and King's College London , 
      London, UK.
FAU - Ahlstedt, Staffan
AU  - Ahlstedt S
AD  - Center of Allergy Research, Institute of Environmental Medicine, Karolinska 
      Insitutet , Stockholm, Sweden.
FAU - Malmstrom, Hakan
AU  - Malmstrom H
AD  - Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet 
      , Stockholm, Sweden.
FAU - Lambe, Mats
AU  - Lambe M
AD  - Regional Cancer Centre, Uppsala, Sweden; Department of Medical Epidemiology and 
      Biostatistics, Karolinska Institutet, Stockholm, Sweden.
FAU - Hammar, Niklas
AU  - Hammar N
AD  - Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, 
      Stockholm, Sweden; AstraZeneca R&D, Molndal, Sweden.
FAU - Walldius, Goran
AU  - Walldius G
AD  - Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, 
      Karolinska Institutet , Stockholm, Sweden.
FAU - Jungner, Ingmar
AU  - Jungner I
AD  - Department of Medicine, Clinical Epidemiological Unit, Karolinska Institutet and 
      CALAB Research , Stockholm, Sweden.
FAU - Ng, Tony
AU  - Ng T
AD  - Richard Dimbleby Department of Cancer Research, Randall Division and Division of 
      Cancer Studies, King's College London , London, UK.
FAU - Van Hemelrijck, Mieke
AU  - Van Hemelrijck M
AD  - Cancer Epidemiology Group, Division of Cancer Studies, King's College London, 
      London, UK; Unit of Epidemiology, Institute of Environmental Medicine, Karolinska 
      Institutet, Stockholm, Sweden.
LA  - eng
GR  - MR/L023091/1/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160328
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
PMC - PMC4938379
OTO - NOTNLM
OT  - Allergy
OT  - atopy
OT  - cancer
OT  - cohort
OT  - immunoglobulin E
EDAT- 2016/07/30 06:00
MHDA- 2016/07/30 06:01
PMCR- 2016/03/28
CRDT- 2016/07/30 06:00
PHST- 2015/12/23 00:00 [received]
PHST- 2016/01/29 00:00 [revised]
PHST- 2016/02/09 00:00 [accepted]
PHST- 2016/07/30 06:00 [entrez]
PHST- 2016/07/30 06:00 [pubmed]
PHST- 2016/07/30 06:01 [medline]
PHST- 2016/03/28 00:00 [pmc-release]
AID - 1154250 [pii]
AID - 10.1080/2162402X.2016.1154250 [doi]
PST - epublish
SO  - Oncoimmunology. 2016 Mar 28;5(6):e1154250. doi: 10.1080/2162402X.2016.1154250. 
      eCollection 2016 Jun.